Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing share allocations for Non-Executive Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding director shareholdings and does not contain financial performance data.
Material Changes
The material change reported is the allocation of notional Ordinary Shares and American Depositary Shares (ADSs) to Non-Executive Directors for the service period of July 1, 2012, to September 30, 2012. The allocations were priced at £14.37 per Ordinary Share and $46.52 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details the notification of director transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: Allocations occurred on September 28, 2012, with notification on October 1, 2012.
- Share Prices: Ordinary Shares allocated at £14.37; ADSs allocated at $46.52.
- Recipients: Allocations were made to Non-Executive Directors including Sir Christopher Gent, Professor Sir Roy Anderson, Dr Stephanie Burns, and others.
- Share Types: Some directors received Ordinary Shares, others received ADSs, and some received both.
- Signatory: The report was signed by Victoria Whyte, Company Secretary, on October 2, 2012.